Supporters so far
HOOFING IT! 2026 Total so far $10,685
Start Hoofing It! Registration is open join a team or start your own Register Now
2025 Results Together we raised $40,662 — thank you to all 150 donors & 11 teams Donate Today
Why It Matters Every step funds NET research, drug access, & patient support across Canada Learn More
Sponsor a Walker Can’t walk? Sponsor a team member — every dollar counts Sponsor Now
2026 Total So Far $10,685 raised of $60,000 — keep on HOOFING IT! Donate Now
HOOFING IT! 2025:
Raised $40,662!

Diagnostic Scan – Ga68

The Gallium 68 scan, used with functional PET imaging, is a nuclear medicine scan that relies on the over-expression of somatostatin receptors to visualize tumours. NETs typically express several somatostatin receptor subtypes in [...]

By |2018-05-07T18:28:11-04:00October 4th, 2017|Treatment News|Comments Off on Diagnostic Scan – Ga68

Somatuline (lanreotide) Access in Manitoba & Alberta

As we advised previously, in July of this year the Manitoba government issued a bulletin http://www.gov.mb.ca/health/mdbif/…/bulletins/bulletin93.pdf that indicated a change in the listing for Somatuline (from 1 to 3 and no access [...]

By |2018-05-07T18:28:11-04:00October 2nd, 2017|Treatment News|Comments Off on Somatuline (lanreotide) Access in Manitoba & Alberta

Caprelsa (vandetanib) for Medullary Thyroid NETs

Caprelsa is indicated for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in adult patients with unresectable locally advanced or metastatic disease.   An application for this drug was [...]

By |2018-05-07T18:28:11-04:00October 2nd, 2017|Treatment News|Comments Off on Caprelsa (vandetanib) for Medullary Thyroid NETs
Go to Top